All
Journal Digest: June 4
This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.
Low-Dose Isotretinoin to Treat Resistant Rosacea
Researchers found evidence from numerous studies claiming LDI could improve rosacea symptoms and decrease flare-ups.
New Study Defines Severity Strata for Vitiligo Using Validated Physician Global Assessment Scores
These findings may provide guidance for future international definitions of degrees of activity and repigmentation in vitiligo.
Upadacitinib Available for Pediatric Patients with pJIA, PsA
Upadacitinib is now available as a tablet or an oral solution for patients 2 years and older with pJIA as well as PsA.
PRP Treatment Boosts Hair Growth and Rebalances Scalp Microbiome in AGA Patients
In a recent study, platelet-rich plasma not only increased hair regrowth but also rebalanced the scalp microbiome in patients with AGA.
POLL: What Skills Are You Most Hoping to Learn at the 2024 SDPA Summer Conference?
With so many sessions and posters, there is a plethora of topics offered at this year's SDPA Summer Conference.
Joseph Zabinski, PhD, MEM: Navigating the Future of AI in Skin Cancer Detection
Zabinski, vice president and head of commercial strategy and AI at OM1, discusses the evolving role of AI in dermatology, focusing on its potential and challenges in skin cancer detection.
Moderna and Merck Announce New 3-Year Date for mRNA-4157 Combined With Pembrolizumab for High-Risk Stage III/IV Melanoma
Phase 3 trials have been initiated in patients with high-risk melanoma.
AARS on Supporting and Educating Patients with Acne
The organization is highlighting stories and resources during Acne Awareness Month through the power of social media.
Q&A: Alexa Kimball, MD, MPH, Talks BE HEARD Data for Hidradenitis Suppurativa
UCB recently announced phase 3 BE HEARD I and II trial results on bimekizumab for treating moderate to severe HS were published in The Lancet.
2024 Fall Clinical Dermatology Conference for PAs and NPs Coverage Recap
Catch up on a weekend full of clinical pearls from the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.
Dermatology Conferences and Meetings Calendar 2024: June
Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.
Day 3 Recap: 2024 Fall Clinical Dermatology Conference for PAs and NPs
Catch up on coverage from the last day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.
Understanding the Mechanism of Action in JAK Inhibitors
Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.
Combining Systemic Therapies in Psoriasis and Atopic Dermatitis
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
Biologics and Pregnancy: A Q&A With Ben Lockshin, MD
Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.
Boxed Warnings: What Should Dermatology Clinicians Know?
Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.
2024 Pediatric Pearls With Karan Lal, DO
The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.
Deciphering Atopic Dermatitis Therapy Options
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
Generalized Pustular Psoriasis: Recent Advancements, Resources, and Cytokine Considerations
Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.
Talking About JAKs: Best Practices for Effective Patient Communication
Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.
Day 2 Recap: 2024 Fall Clinical Dermatology Conference for PAs and NPs
Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.
Derm In The News: May 26-June 1
Keep up with the latest headlines in dermatology from the past week, including US sunscreen versus global regulations, all-time high melanoma rates in the UK, and more.
Integrating Vaccination Guidelines in Dermatology
Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.
Unraveling the Advancements in Seborrheic Dermatitis Treatment
Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.
Navigating the Alopecia Areata Treatment Landscape
James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.
Exploring Oral Options for Psoriasis Therapies
Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.
Efficacy of Dupilumab in Treating Atopic Hand and Foot Dermatitis
The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.
Day 1 Recap: 2024 Fall Clinical Dermatology Conference for PAs and NPs
Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.
Treating Chronic Spontaneous Urticaria: Findings from the LIBERTY-CSU CUPID Study A
Improvements persisted through the 12-week post-treatment follow-up, indicating sustained efficacy even after discontinuation of dupilumab.